Shilpa Medicare announced the launch of Indian branded generic of Dasatinib, an anticancer drug with a brand name DASASHIL. DASASHIL is First Branded Generic Anticancer Drug with all dosage strength 20/ 50/
70/ 100 mg tablets which is used for the treatment of Chronic Myeloid Leukaemia (CML)
The Drug Substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 2020.
Current, monthly therapy cost of innovator is approximately 1.65 Lacs, with the launch of DASASHIL monthly cost of treatment will be reduced drastically to Rs. 6440/- as monthly therapy cost.
The products are being manufactured and supplied from the state-of-the-art US-FDA approved manufacturing facility.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
